Foundation Medicine, Inc. is a public American company based in Cambridge, Massachusetts which develops, manufactures and sells genomic analysis diagnostics for solid and circulating cancers. The company's tests are based on next-generation sequencing technology.
Foundation Medicine went public in August 2013; its stock is traded on the New York Stock Exchange under the symbol FMI. In 2015, revenue reached $93 million. As of March 2016, the company had 417 employees.
The company's flagship product was FoundationOne, the FoundationOne Heme diagnostic test being for blood cancers.
In November and December 2014, the company established agreements with COTA and Flatiron Health, respectively, aimed at increasing the volume of genomic and clinical patient data available to it. In 2015, Roche announced a plan to purchase a 56.3% stake in the company through a US$780,000,000 purchase of newly issued shares. Roche also announced an intention to invest US$400,000,000 toward Foundation Medicine's operations, development and R&D activities.
|Key people||Michael J. Pellini (CEO) Steve Kafka (COO) David Daly (CCO)|
|Headquarters||Cambridge, Massachusetts, United States|
|Owners||Hoffmann-La Roche (56%, 2015)|
NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.
It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.
The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.
Net Promoter Score is a number from -100 from 100.
Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.
The industry average for Health Care / Medical Specialities is 0.
The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.
Consider an example: If Foundation Medicine, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.
Therefore, comparing the NPS score of Foundation Medicine, Inc. with your own without any further context is not that useful.
What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.
How are your customers satisfied depending on:
|CIGNA||Insurance / Health and Life Insurance||-1|
|Vodafone||Telecommunications / Wireless Carrier||-1|
|Chase||Financial Services / Banking||-1|
|Cleeng||Technology / Software||1|
|Fifth Third Bank||Financial Services / Banking||1|
|Accenture Consulting||Technology / Other||1|
|Dish||Telecommunications / Cable/TV service||1|
|Morrisons||Consumer Brands / Grocery||2|
|Mediacom||Consumer Brands / Entertainment||2|
|ESPN||Consumer Brands / Entertainment||2|
We have estimated the Net Promoter Score of Foundation Medicine, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.
Do you think this information is incorrect? Report incorrect information. Do you have more accurate data? Submit NPS score.